SCHEMBL15533247

SCHEMBL15533247

CC(C)NCc1cn(COCC[Si](C)(C)C)c2ncccc12

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 1/20 0.34
▸ IGF1R P08069 1/20 0.34
▸ SRC P12931 1/20 0.34
▸ FLT4 P35916 1/20 0.34
▸ KDR P35968 1/20 0.34
▸ FLT3 P36888 1/20 0.34
▸ EPHB4 P54760 1/20 0.34
▸ TEK Q02763 1/20 0.34
▸ DGAT1 O75907 1/20 0.33
▸ GSK3B P49841 2/20 0.32
▸ CYP2C19 P33261 2/20 0.32
▸ HIF1A Q16665 1/20 0.32
▸ ADRA2C P18825 1/20 0.32
▸ NPC1 O15118 2/20 0.32
▸ HTR2A P28223 3/20 0.32
▸ HTR2C P28335 3/20 0.32
▸ HTR2B P41595 3/20 0.32
▸ CNR1 P21554 2/20 0.32
▸ CNR2 P34972 2/20 0.32
▸ HDAC3 O15379 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30848403 0.82 NPC1 (0.36) EGFRIGF1RSRCFLT4KDR
SCHEMBL30848448 0.81 HTR6 (0.37) EGFRIGF1RSRCFLT4KDR
SCHEMBL19260864 0.80 DGAT1 (0.34) EGFRIGF1RSRCFLT4KDR
SCHEMBL31050029 0.78 DGAT1 (0.40) EGFRIGF1RSRCFLT4KDR
SCHEMBL29748840 0.77 DGAT1 (0.41) EGFRIGF1RSRCFLT4KDR
SCHEMBL21044790 0.77 DGAT1 (0.41) EGFRIGF1RSRCFLT4KDR
SCHEMBL29514362 0.74 ELANE (0.47) MAPTHTTL3MBTL1ELANE
SCHEMBL15546774 0.74 POLB (0.39) EGFRIGF1RSRCFLT4KDR
SCHEMBL30168307 0.74 CNR1 (0.46) CNR1CNR2KDM4EMAPTL3MBTL1
SCHEMBL25001937 0.74 CNR1 (0.45) NPC1CNR1CNR2ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9181261-B2 TrkA kinase inhibitors, compositions and methods thereof MERCK SHARP & DOHME CORP. (US) 2015-11-10 — — US disclosed
US-20150141428-A1 TrkA Kinase Inhibitors, Compositions and Methods Thereof MERCK SHARP & DOHME CORP. (US) 2015-05-21 — — US disclosed
EP-2858501-A1 TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF Merck Sharp & Dohme Corp. (US) 2015-04-15 — — EP disclosed
WO-2013176970-A1 TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF MERCK SHARP & DOHME CORP. (US) 2013-11-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150141428-A1 TrkA Kinase Inhibitors, Compositions and Methods Thereof NGF, NGFR, NTRK1 EGFR 61/4885IGF1R 640/4885SRC 202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback